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Introduction
Decay accelerating factor (DAF or CD55) is a cell surface regulator which prevents activation of serum complement proteins on cell surfaces and thereby protects self-cells from complement mediated injury (1) . Our project started with our unexpected observation (2) that induction of T cell effector cell responses with dendritic cells (DCs) devoid of DAF ex vivo can augment anti-tumor immunoreactivity. During the course of our studies, we surprising discovered that DAF not only controls immune cell proliferation associated with anti-cancer T effector response, but also controls cancer cell proliferation itself, as well as controls its associated angiogenesis. The underlying mechanism is that contrary to generally held concepts that complement resides exclusively in serum and derives solely from the liver, all cells (studied to date) locally synthesize alternative pathway (AP) complement components C3, factor B (fB), and factor D (fD) together with C5. These components spontaneously activate on the cell surface to produced C3a and C5a. The C3a/C5a anaphyotoxins feed-back to interact with C3a and C5a receptors (C3aR/C5aR) on the same cells and the resulting autocrine signaling drives cell growth and functions to prevent apoptosis. It is noteworthy that prior work by others (3) on cancer focused on using anti-DAF antibodies to inhibit DAF's serum complement shielding function, with the idea that this blockade would lead to cancer cell cytotoxicity. Counter intuitively, such blockade, in fact, functions to augment cancer call growth, as the antibodies generate C3a/C5a from serum C3/C5at the cancer cell surface which can amplify cancer cell C3aR/C5aR signaling. We later learned that the mitotic and antiapoptotic activities of epidermal growth factor receptor (EGFR, Her-2) in cancer cells and vascular endothelial growth factor receptor 2 (VEGFR2) signaling in vascular endothelial cells (ECs) depend on C3aR/C5aR signaling. While one would hypothesize that blockade of C3aR/C5aR signaling would inhibit all of these cancer promoting activities that drive tumor progression, we have found that C3aR/C5aR blockade blocks the anti-cancer cell T effector cell response and concurrently induces Foxp3 + T regulatory cells (Tregs). Consequently, for immune inhibition of cancers, one must deal with the tumor, and its microenvironment as well as the anti-tumor immune response. Studies extending our statements of work to focus on this key insight were approved in prior progress reports. In the last year's progress report, we summarized our findings concerning the integral role that C3aR/C5aR signaling plays in EGFR/Her-2 growth induction of cancers and VEGF-A induction of angiogenesis. We presented in vivo data confirming decreased tumor mass and decreased tumor associated angiogenesis in mice devoid of C3aR/C5aR signaling. The mechanism had not yet been clarified. In the past year, we have found that IL-6gp130 signaling participates in this growth and anti-apoptotic signaling. As previously indicated, our experiments in ECs had shown that VEGF-A induced proliferation of ECs was blocked by pharmaceuticals against the receptors (C3aR-A/C5aR-A) or mAbs against the C3a/c5a ligands and that added C5a induces the cell cycle entry and growth of ECs comparably to added VEGF-A. Based on this, we examined VEGFR2 phosphorylation. We found that the added C5a, like added VEGF-A, induced VEGFR-2 phosphorylation in < 5 min, suggesting that C5aR and VEGFR-2 might be physically associated (Fig 1) . In view of our prior connection of C5a generation with IL-6 receptor (IL-6R) signaling in immune cells, we tested whether IL-6R signaling might also participate in the interconnection of C5aR with VEGFR-2 in ECs. As indicated last year, we found that both processes, which are known to activate STAT3 (4-7), were abolished by C3aR/C5aR antagonism (Fig 2) . Based on these findings, we assayed culture supernatants of a) VEGF treated ECs, b) IL-6 treated ECs, and c) C5a treated ECs for VEGF, C5a, and IL-6 at increasing times. Remarkably, all three ligands were tonically produced by the ECs and each ligand stimulated 4-fold increases in VEGF, C5a, and IL-6 at 4 h (Fig 3) . Based on this, we added VEGF-A to ECs for 5 min, and probed immunoblots of anti-C5aR, anti-gp-130 and, anti-VEGFR2 immunoprecipitates (IPs) with antibodies to each of the other components. This showed that all three coimmunoprecipitate (co-IP) and are associated (Fig 4) . These findings implicate both C3aR/C5aR and IL6Rgp130 signaling in VEGFR-2 induction of EC growth. Findings by others of a second phase of STAT3 phosphorylation at 4 h coincides with this. A corresponding set of data were obtained for EGFR, IL-6Rgp130 and p-STAT3 in breast cancer cells. The finding that C5a induces VEGFR-2 phosphorylation in <5 min time and the pull-down of C5aR, gp130, and VEGFR-2 by mAbs to each other implicate a signaling complex (signalosome) involving all three receptors. Mass Spec (MS) and liquid chromatography (LC)-MS-MS analyses are in progress to confirm this complex, identify potential additional partners, and determine phosphorylations. In addition to C3aR/C5aR antagonism in conjunction with IL-6 blockade, we expect that this analysis will open up new targets for clinical intervention. We have examined the effect of inhibiting C3aR/C5aR signaling on two cancer lines in which EGFR signaling is deregulated. The blockade in both cases inhibited their growth (Fig 5) . In addition to characterizing the signalosome, we plan to assay EGF, C3a/C5a, and IL-6 production, and STAT3 phosphorylation kinetically in these and other breast cancer lines.
2) Transfection of DCs and breast cancer cells with DAF, Crry and DAF/Crry and C3aR/C5aR siRNAs. In our prior report, we emphasized the importance of inhibiting DAF regulatory activity and consequently potentiating C3aR/C5aR signaling selectively immune cells while doing the reverse in cancer cells and tumor associated ECs. We presented data showing both siRNA and shRNA knockdown of C3aR and C5aR in NMuMG breast cancer cells and in DCs. While this methodology allows in vitro studies and short term in vivo studies of cancers silenced in these genes, it does not allow in vivo studies in which the role of DAF control of C3aR/C5aR signaling in cancer cell progression can be precisely defined. To make such studies feasible, we reported last year that we initiated efforts to prepare conditional + cell selective knockout of DAF, C3aR, C5aR or both C3aR/C5aR will allow analysis of the interaction of the cancer with its microenvironment. Our data indicate that the optimal approach would be to selectively increase C3a/C5a production in immune cells and disable C3aR/C5aR signaling elsewhere. This could be done by administering tumor cells silenced in C3aR/C5aR signaling to mice in which Daf1 is selectively knocked out in immune cells and C3aR/C5aR signaling selectively knocked out in ECs.
3): Preparation of and studies with Adenoviruses expressing C5a, C3a and both anaphylatoxins. We provided evidence last year that both CD4 + cells and ECs locally produce thrombin which can cleave EC produced C5 to C5a. As discussed in 1) above, our data showed that added C5a transactivates to phosphorylate VEGFR2 and that VEGF-A induction of VEGFR2 phosphorylation is blocked by C3aR/C5aR antagonists. We have similar results for EGFR signaling. Consequently this is a second pathway that can drive cancer growth itself as well as its associated angiogenesis. These findings may explain the numerous reports connecting cancer growth with thrombin (8) and cancer cell thrombin with IL-6 (9, 10). We are analyzing breast cancers for production of thrombin and the effects of inhibiting thrombin on breast cancer C5a production on proliferation, clot formation, and circumvention of apoptosis.
4): Anti-breast tumor T cell responses in Daf1
-/-, Daf1 -/-Crry -/+ and wild-type mice: In last years' report, we summarized our unique findings that absent C3aR/C5aR signaling in CD4 + cells enables their endogenous TGF-β1 production and their differentiation into Foxp3 + T regulatory cells, which are widely known to be responsible for the circumvention by breast (and other) cancers of anti-tumor cell T effector responses (11) (12) (13) This contrasts with potentiated C3aR/C5aR signaling which drives Th1/Th17 effector cell responses (14) . While we described the connection of C3aR/C5aR signaling with the PI-3Kγ-AKT-mTOR pathway in our previous progress report, we discovered that absent C3aR/C5aR signaling is needed for PKA activation of p-CREB, that disabled AKT phosphorylation is needed to de-repress nuclear translocation of Foxo-1 and that absent C3aR/C5ar signaling is needed for phosphorylation STAT5, three transcription factors needed for Foxp3 gene expression. We additionally found that absent C3aR/C5aR signaling causes up-regulation of C5L2, an alternative C5a receptor decoy receptor which scavenges C5a (and C3a) (15, 16) and prevents C3aR/C5aR receptor signaling. These paradigm shifting data were recently published in Nature Immunology (17) . We are testing how this pathway is altered in breast cancers. Since all cells including cancers (tested to date) express C3aR/C5aR and endogenously produce C3a/C5a which enter into autocrine signaling loops which drive their growth, this must be taken into consideration for enhancing the T effector response. As indicated in last year's report, we plan studies with conditional knockouts and implanted cancers silenced in C3aR/C5aR signaling to test this.
5)
In vivo studies with the transfectants and adoptive transfer studies: This was discussed in Statements of work 2 and 4. 6) Silencing of DAF and Crry in DCs: This was discussed in Statement of work 2: 7) Boosting local C5a/C3a production by DCs: This would be done with DCs from mice conditionally knocked out in Daf1 as was discussed in Statement of work 2.
Key Research Accomplishments
1): Finding that VEGFR2 and EGFR exist with C5aR and IL-6Rgp130 in a plasma membrane signaling complex, i.e. signalosome, that the C5a, IL-6, and VEGF-A or EGF ligands are endogenously produced by cells, and that autocrine signaling by each ligand drives the production of the other, and that this process underlies VEGF-A and EGF induced proliferation.
2): Finding that all three receptors transmit their signaling via activation of STAT3.
3): Finding that C5aR signaling is needed for VEGFR2 phosphorylation. 
Reportable Outcomes
Autocrine C3aR/C5aR signaling and its regulation by DAF are not only integrally involved in controlling the anti-tumor immune response, i.e. biasing between Th1/Th17 effector cell vs Treg commitment, but also directly involved in controlling the growth of cancer cells themselves as well as their associated angiogenesis.
Conclusion
C3aR/C5aR signaling must be augmented for enhancing the anti-breast cancer cell effector cell response and preventing cancer specific Tregs, but simultaneously suppressed in the cancer and in ECs to suppress breast cancer growth. To accomplish this, T effector must be primed with tumor antigen and DCs ex vivo and returned to patients under conditions in which C3aR/C5aR and IL-6 signaling is suppressed. For an optimal effect, methods are needed to target this suppression to cancers and endothelial cells. Others listed last year. Extended data on signalosome added this year.
